Investor Relations

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Corporate Profile

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Latest Presentations

SEC Filings

Filing date Description Form

An amendment to the SC 13G filing

SC 13G/A

An amendment to the SC 13G filing

SC 13G/A

An amendment to the SC 13G filing

SC 13G/A